ENTERIN, INC.

Profile

Company Names

ENTERIN, INC.

Addresses

2005 MARKET STREET, SUITE 3125, PHILADELPHIA, PA 19103

3624 MARKET STREET, SUITE 517, PHILADELPHIA, PA 19104

Phone Numbers

617-832-1767
202-444-6396

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY, OTHER HEALTH CARE, PHARMACEUTICALS

Year Incorporated:

2014

State Incorporated:

DELAWARE

Total Amount Raised:

$50,655,945.00

Number of Funding Rounds:

6
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
6
2023-11-21 
$5,099,772.00 
$19,999,973.00 
$14,900,201.00 
Equity 
5
2022-08-30 
$6,000,000.00 
$20,000,000.00 
$14,000,000.00 
Debt 
4
2021-09-23 
$5,685,438.00 
$32,000,000.00 
$26,314,562.00 
Debt 
3
2020-09-08 
$11,703,493.00 
$19,999,941.00 
$8,296,448.00 
Equity 
2
2019-01-11 
$16,699,970.00 
$25,000,000.00 
$8,300,030.00 
Equity 
1
2017-06-30 
$5,467,272.00 
$12,717,276.00 
$7,250,004.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
DENISE 
 
BARBUT 
EXECUTIVE OFFICER, DIRECTOR
COAXIA INC   |  BENECHILL, INC.   |  SARENTIS THERAPEUTICS INC   |  SARENTIS OPHTHALMIC INC   |  ASTUCE, INC.   |  ENIGMA MEDICAL, INC.   |  CLEPSYDRA, INC.   |  VIGILANT MEDICAL SOLUTIONS, INC.   |  NOVO BIOSCIENCES, INC.   |  ENTERIN, INC.
STUART 
 
BARLOW 
EXECUTIVE OFFICER
ENTERIN, INC.
JAY 
 
BRAMMER 
EXECUTIVE OFFICER, DIRECTOR
ENTERIN, INC.
JAY 
A 
BRAMMER 
DIRECTOR
ENTERIN, INC.   |  METABOLICS PHARMA, INC.
JAY 
A. 
BRAMMER 
DIRECTOR
INDIE DIVERSIFIED ASSET FUND, L.P.   |  INDIE DIVERSIFIED INCOME FUND, LLC   |  INDIE DIVERSIFIED ABSOLUTE RETURN FUND, LLC   |  ENTERIN, INC.   |  INDIE DIVERSIFIED INCOME FUND II, LLC
MARK 
 
FINN 
DIRECTOR
CIBUS GLOBAL, LTD.   |  ENTERIN, INC.   |  FIRST LANDING FUND, LLC   |  NEW VENTURES III, LLC   |  ROYALTY PORTFOLIO SERIES VANTAGE MULTI-STRATEGY FUND L.P.   |  AVIATION SERIES VANTAGE MULTI-STRATEGY FUND L.P.   |  ABODE TECHNOLOGIES, INC.   |  UNREAL ESTATE INC.   |  AVIATION SERIES 2 VANTAGE MULTI-STRATEGY FUND L.P.   |  METABOLICS PHARMA, INC.   |  VANTAGE RODESSA FUND LP
WILLIAM 
 
KINNEY 
EXECUTIVE OFFICER
KANNALIFE INC   |  NEUROPATHIX, INC.   |  ENTERIN, INC.
RICHARD 
 
LARSON 
EXECUTIVE OFFICER
FELSUMA LLC   |  TRIOPSY MEDICAL, INC.   |  ENTERIN, INC.   |  METABOLICS PHARMA, INC.   |  PULSAR AI GROWTH SPV 1, LLC
DAVID 
 
MCCULLOUGH 
EXECUTIVE OFFICER, DIRECTOR
LEASEACCELERATOR, INC.   |  ENTERIN, INC.   |  AKERNA CORP.
BARRY 
 
MILLER 
DIRECTOR
VOLORIDGE GLOBAL FUND,LP   |  VOLORIDGE TRADING FUND, LP   |  VOLORIDGE AGGRESSIVE FUND, LP   |  VOLORIDGE GLOBAL FUND, LTD.   |  VOLORIDGE TRADING AGGRESSIVE FUND, LP   |  VOLORIDGE TRADING AGGRESSIVE FUND, LTD.   |  VOLORIDGE FUND, LTD.   |  VOLORIDGE FUND, LP   |  VOLORIDGE SUSTAINABILITY FUND, LP   |  VOLORIDGE SUSTAINABILITY FUND, LTD.   |  VOLORIDGE CLIMATE CHANGE FUND, LTD.   |  VOLORIDGE CLIMATE CHANGE FUND, LP   |  ENTERIN, INC.   |  METABOLICS PHARMA, INC.   |  ARES SECONDARIES INFRASTRUCTURE SOLUTIONS III FEEDER, SCSP   |  ARES SECONDARIES INFRASTRUCTURE SOLUTIONS III OFFSHORE, L.P.   |  ARES SECONDARIES INFRASTRUCTURE SOLUTIONS III, L.P.
ROGER 
 
MILLS 
DIRECTOR
ADDEX THERAPEUTICS LTD.   |  ENTERIN, INC.   |  MILLS ELOGE INVESTMENTS, LLC, SERIES 2   |  MILLS ELOGE INVESTMENTS, LLC, SERIES 4   |  MILLS ELOGE INVESTMENTS, LLC, SERIES 3
DON 
 
MUNOZ 
DIRECTOR
ENTERIN, INC.
NANCY 
 
NESS 
EXECUTIVE OFFICER
LUMEN BIOMEDICAL INC   |  K SPINE, INC.   |  INTERRAD MEDICAL, INC.   |  AUM CARDIOVASCULAR, INC.   |  AUM CARDIOVASCULAR, INC.   |  POPS! DIABETES CARE, INC.   |  ENTERIN, INC.
RICHARD 
 
PROPPER 
DIRECTOR
AXIALMED, INC.   |  FREELINC TECHNOLOGIES INC.   |  ENTERIN, INC.   |  HYEDGE, INC.   |  D2 PHARMA CONSULTING LLC   |  RMX INDUSTRIES, INC.
DAVID 
 
VOGEL 
DIRECTOR
CIDRA HOLDINGS LLC   |  VOLORIDGE GLOBAL FUND,LP   |  VOLORIDGE TRADING FUND, LP   |  VOLORIDGE AGGRESSIVE FUND, LP   |  VOLORIDGE TRADING AGGRESSIVE FUND, LP   |  VOLORIDGE FUND, LP   |  VOLORIDGE SUSTAINABILITY FUND, LP   |  VOLORIDGE CLIMATE CHANGE FUND, LP   |  UBIETY TECHNOLOGIES, INC.   |  ENTERIN, INC.   |  BADGER BEVS, LLC   |  CARNA INC.
KATHERINE 
 
WOLF 
EXECUTIVE OFFICER, DIRECTOR
VISION SCIENCES INC /DE/   |  ENTERIN, INC.
MICHAEL 
 
ZASLOFF 
EXECUTIVE OFFICER, DIRECTOR
FORMULA XO, INC.   |  ENTERIN, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2023-12-06
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2023-11-21 
2022-09-12
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Debt 
2022-08-30 
2021-10-08
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2021-09-23 
2020-09-16
D
Link
OTHER HEALTH CARE 
 
DECLINE TO DISCLOSE 
Equity 
2020-09-08 
2019-01-28
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2019-01-11 
2017-07-14
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2017-06-30 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#